Influencing factors of female sexual dysfunction in Chinese women

doi:10.3969/j.issn.1006-7795.2022.03.005

Abstract

Abstract: Objective To investigate the risk factors of female sexual dysfunction (FSD) in Chinese women and to provide clinical evidences for improving perimenopausal and postmenopausal women's quality of life. Methods A multicenter clinical study was conducted among 902 women in the Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University and other two medical alliance institutions from April 2020 to March 2021. Socio-demographic, behavioral and clinical data were collected. The anthropometric indices of each subject were measured. FSD were evaluated using the Female Sexual Function Index (FSFI) and the subjects were divided into two groups according to the FSFI: FSD group and no FSD group. According to the 2011 stages of the Reproductive Ageing Workshop (STRAW+10) and postmenopausal women using menopause hormone therapy (MHT) or not, the subjects were divided into seven stages, Modified Kupperman Index (KMI) for climacteric syndromes, The Patient Health Questionnaire-9 (PHQ-9) for depression, the International Consultation on Incontinent Questionnaire (ICIQ) for stress urinary incontinence, the Overactive Bladder Symptom Score (OABSS) for overactive bladder. According to the obtained results, univariate and multivariate Logistic regression analyses were performed. Results Multivariate regression analysis revealed that KMI (OR=1.061,95%CI:1.039-1.083),follicle stimulating hormone (FSH) (OR=1.008,95%CI:1.002-1.014),below secondary education level (OR=1.446,95%CI:1.019-2.052), depress (OR=1.814,95%CI:1.156-2.845), early postmenopausal stage (OR=1.717,95%CI:1.106-2.667), late postmenopausal stage (OR=1.905,95%CI:1.008-3.602), neutral marital relationship (OR=2.422,95%CI:1.711-3.429) and dissatisfaction marital relationship (OR=1.945,95%CI:1.018-3.717) were the important risk factors for FSD (P<0.05). Femoston was the protective factor for FSD in early menopausal women(OR=0.229,95%CI:0.059-0.889) (P<0.05). Conclusion Many psychological, physiological and social factors induce FSD. Ovarian function failure is an important risk factor for FSD. MHT was shown to have a beneficial effect on FSD.

Key words: female sexual dysfunction, risk factor, STRAW+10 criteria, menopause, hormone therapy, FSFI, sex hormone

CLC Number:

R711.75

Ju Rui, Ruan Xiangyan, Dai Yinmei, Bai Yongtao, Yang Yu, Xu Xin, Cheng Jiaojiao, Yang Xingzi, Shi Yanhong, Sun Yanhua, Li Ruiling. Influencing factors of female sexual dysfunction in Chinese women[J]. Journal of Capital Medical University, 2022, 43(3): 357-363.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2022.03.005

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2022/V43/I3/357

References

[1] Heidari M, Sheikhi R A, Rezaei P, et al. Comparing quality of Life of elderly menopause living in urban and rural areas[J]. J Menopausal Med, 2019, 25(1): 28-34.
[2] 朱兰, 娄文佳. 重视女性性功能障碍疾病[J]. 实用妇产科杂志, 2018, 34(6): 401-402.
[3] American College of Obstetricians and Gynecologists' Committee on Practice Bulletins-Gynecology. Female sexual dysfunction: ACOG practice bulletin clinical management guidelines for obstetrician-gynecologists, number 213[J]. Obstet Gynecol, 2019, 134(1): e1-e18.
[4] Ju R, Ruan X Y, Xu X, et al. Importance of active and passive smoking as one of the risk factors for female sexual dysfunction in Chinese women[J]. Gynecol Endocrinol, 2021, 37(6): 541-545.
[5] 鞠蕊, 阮祥燕, 代荫梅, 等. 不同生殖衰老分期及激素替代治疗的绝经期女性性功能障碍状况分析[J]. 首都医科大学学报, 2021, 42(4): 533-539.
[6] 鞠蕊, 阮祥燕, 许新, 等. 围绝经期及绝经后女性性功能障碍状况及与更年期症状的关系分析[J]. 首都医科大学学报, 2020, 41(4): 503-507.
[7] Harlow S D, Gass M, Hall J E, et al. Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging[J]. Climacteric, 2012, 15(2): 105-114.
[8] Sun X G, Li C Y, Jin L N, et al. Development and validation of Chinese version of female sexual function index in a Chinese population: a pilot study[J]. J Sex Med, 2011, 8(4): 1101-1111.
[9] Williams L S, Brizendine E J, Plue L, et al. Performance of the PHQ-9 as a screening tool for depression after stroke[J]. Stroke, 2005, 36(3): 635-638.
[10] Blaivas J G, Panagopoulos G, Weiss J P, et al. Validation of the overactive bladder symptom score[J]. J Urol, 2007, 178(2): 543-547.
[11] Thomas H N, Neal-Perry G S, Hess R. Female sexual function at midlife and beyond[J]. Obstet Gynecol Clin North Am, 2018, 45(4): 709-722.
[12] McCool-Myers M, Theurich M, Zuelke A, et al. Predictors of female sexual dysfunction: a systematic review and qualitative analysis through gender inequality paradigms[J]. BMC Womens Health, 2018, 18(1): 108.
[13] 金凤羽, 阮祥燕, Alfred O M, 等. 北京及周边地区围绝经期女性性功能现状调查分析[J]. 首都医科大学学报, 2017, 38(4): 509-514.
[14] Tong J, Zhang C, Zhu L, et al. Sexual dysfunction in perimenopausal women based on a national epidemiological survey in China[J]. Climacteric, 2019, 22(2): 190-194.
[15] Lou W J, Chen B, Zhu L, et al. Prevalence and factors associated with female sexual dysfunction in Beijing, China[J]. Chin Med J (Engl), 2017, 130(12): 1389-1394.
[16] Heidari M, Ghodusi M, Rezaei P, et al. Sexual function and factors affecting menopause: a systematic review[J]. J Menopausal Med, 2019, 25(1): 15-27.
[17] Kong F, Wang J, Zhang C, et al. Assessment of sexual activity and menopausal symptoms in middle-aged Chinese women using the Menopause Rating Scale[J]. Climacteric, 2019, 22(4): 370-376.
[18] Baber R J, Panay N, Fenton A, et al. 2016 IMS recommendations on women's midlife health and menopause hormone therapy[J]. Climacteric, 2016, 19(2): 109-150.
[19] Weinberger J M, Houman J, Caron A T, et al. Female sexual dysfunction: a systematic review of outcomes across various treatment modalities[J]. Sex Med Rev, 2019, 7(2): 223-250.
[20] Laumann E O, Paik A, Glasser D B, et al. A cross-national study of subjective sexual well-being among older women and men: findings from the Global Study of Sexual Attitudes and Behaviors[J]. Arch Sex Behav, 2006, 35(2): 145-161.
[21] Jiann B P, Su C C, Yu C C, et al. Risk factors for individual domains of female sexual function[J]. J Sex Med, 2009, 6(12): 3364-3375.
[22] Shifren J L, Monz B U, Russo P A, et al. Sexual problems and distress in United States women: prevalence and correlates[J]. Obstet Gynecol, 2008, 112(5): 970-978.
[23] Zhang H P, Yip P S F. Female sexual dysfunction among young and middle-aged women in Hong Kong: prevalence and risk factors[J]. J Sex Med, 2012, 9(11): 2911-2918.
[24] Cappelletti M, Wallen K. Increasing women's sexual desire: the comparative effectiveness of estrogens and androgens[J]. Horm Behav, 2016, 78: 178-193.
[25] Ruan X Y, Mueck A O. Chinese obstetrician-gynecologists still need more education in menopausal hormone therapy[J]. Menopause, 2014, 21(11): 1170-1172.
[26] Stevenson J C, Panay N, Pexman-Fieth C. Oral estradiol and dydrogesterone combination therapy in postmenopausal women: review of efficacy and safety[J]. Maturitas, 2013, 76(1): 10-21.